跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
INHBE
首页
药物
INHBE
INHBE
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
METHODS OF TREATING METABOLIC DISORDERS AND CARDIOVASCULAR DISEASE WITH INHIBIN SUBUNIT BETA E (INHBE) INHIBITORS
EP 4259279 A1
申请人: REGENERON PHARMA
优先权: 2020
EP
US
WO
9 件公开
RNAI AGENTS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE), PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE
EP 4771156 A1
申请人: ARROWHEAD PHARMACEUTICALS INC
优先权: 2023
CN
EP
US
WO
6 件公开
COMPOSITIONS AND METHODS FOR INHIBITION OF EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) GENES
EP 4677094 A2
申请人: BASECURE THERAPEUTICS LLC
优先权: 2023
CN
EP
US
WO
5 件公开
WO 2025193754 A3
申请人: BASECURE THERAPEUTICS LLC
优先权: 2024
WO
SIRNA TARGETING INHIBIN ?E, SIRNA CONJUGATE, AND MEDICAL USE THEREOF
EP 4674965 A1
申请人: TUOJIE BIOTECH SHANGHAI CO LTD
优先权: 2023
CN
EP
US
WO
4 件公开
INHBE GENE-TARGETED DOUBLE-STRANDED OLIGONUCLEOTIDE, CONJUGATE, COMPOSITION AND USE THEREOF
EP 4768583 A1
申请人: RIGERNA THERAPEUTICS SUZHOU CO LTD
优先权: 2023
CN
EP
WO
3 件公开
INHIBIN SUBUNIT BETA E-RELATED DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO
EP 4770650 A2
申请人: WAVE LIFE SCIENCES LTD
优先权: 2023
CN
EP
WO
3 件公开
WO 2025235911 A3
申请人: WAVE LIFE SCIENCES LTD
优先权: 2024
WO
WO 2026055502 A2
申请人: WAVE LIFE SCIENCES LTD
优先权: 2024
WO
INHIBIN SUBUNIT BETA E (INHBE) MODULATOR COMPOSITIONS AND METHODS OF USE THEREOF
US 20250051779 A1
申请人: ALNYLAM PHARMACEUTICALS INC
优先权: 2021
CN
US
2 件公开
INHIBITOR FOR INHIBITING EXPRESSION OF INHIBIN BETA E GENE AND USE THEREOF
WO 2025082057 A9
申请人: RISEN SHANGHAI MEDICINAL TECH CO LTD
优先权: 2023
CN
WO
2 件公开
GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC INHBE
WO 2025131079 A1
申请人: BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD
优先权: 2023
CN
WO
2 件公开
COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE)
WO 2025131019 A1
申请人: SHANGHAI ARGO BIOPHARMACEUTICAL CO LTD
优先权: 2023
CN
WO
2 件公开
第 1 / 4 页
上一页
下一页
药物
反馈